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http://dx.doi.org/10.1016/j.ccr.2014.03.011SUMMARYMEK inhibitors are clinically active in BRAFV600E melanomas but only marginally so in KRAS mutant tumors.
Here, we found that MEK inhibitors suppress ERK signaling more potently in BRAFV600E, than in KRAS
mutant tumors. To understand this, we performed an RNAi screen in a KRAS mutant model and found that
CRAF knockdown enhanced MEK inhibition. MEK activated by CRAF was less susceptible to MEK inhibitors
than when activated by BRAFV600E. MEK inhibitors induced RAF-MEK complexes in KRAS mutant models,
and disrupting such complexes enhanced inhibition of CRAF-dependent ERK signaling. Newer MEK inhibi-
tors target MEK catalytic activity and also impair its reactivation by CRAF, either by disrupting RAF-MEK
complexes or by interacting with Ser 222 to prevent MEK phosphorylation by RAF.INTRODUCTION
Oncogenic KRAS mutations are common in cancer. Active RAS
mediates its effects on tumor formation through a number of
effector proteins, including RAF, PI3K, and RAL (Blasco et al.,
2011; Gonza´lez-Garcı´a et al., 2005; Gupta et al., 2007; Kolch
et al., 1991). Active RAS causes dimerization and activation of
RAFkinases.This initiatesasignalingcascade inwhichRAFphos-
phorylates and activates MEK, which in turn phosphorylates and
activates ERK (reviewed in Schubbert et al., 2007; Wellbrock
et al., 2004). Under physiologic conditions, the amplitude and
duration of ERK signaling are regulated by ERK-dependent feed-Significance
We show that the effects of MEK inhibitors in KRASmutant tum
these tumors, someMEK inhibitors induce CRAF-MEK comple
compounds associate with MEK differently and are affected le
and structural approaches, we identified two allosteric effects
tumors: increasing the dissociation of MEK from RAF or causin
phorylated by RAF. Designingmore effective compounds for tr
action in the appropriate genetic context.back inhibition of multiple components of the pathway, including
receptors, exchange factors, CRAF, and ERK itself (Dong Chen
etal., 1996;Doughertyetal., 2005;DouvilleandDownward,1997).
The importance of ERK signaling in cancers with mutant RAS
has been demonstrated in experimental systems in which ge-
netic and pharmacologic manipulation shows that this cascade
is required for tumor initiation and maintenance (reviewed in
Pylayeva-Gupta et al., 2011). The widespread importance of
ERK signaling in cancer is also demonstrated by the frequent
occurrence of mutations in other members of this pathway,
especially BRAF mutations that occur frequently in melanomas,
thyroid, and other cancers (Davies et al., 2002).ors vary, owing to specific properties of drug-boundMEK. In
x formation, which prevents durable inhibition of ERK. Newer
ss by reactivated CRAF. Through genetic, pharmacological,
that improve the efficacy of MEK inhibitors in KRAS mutant
g MEK to adapt a conformation in which it cannot be phos-
eating cancer requires understanding themechanism of drug
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Effective MEK Inhibition in KRAS Mutant TumorsRAF and MEK inhibitors have been developed as potential
therapeutics in an effort to inhibit the growth of tumors depen-
dent on ERK signaling (Bollag et al., 2012; McCubrey et al.,
2010; Sebolt-Leopold et al., 1999). RAF inhibitors inhibit ERK
signaling in tumors harboring BRAFV600E/K mutations (Heidorn
et al., 2010; Joseph et al., 2010; Poulikakos et al., 2010) and
have remarkable therapeutic activity in melanomas harboring
these mutations (Bollag et al., 2010; Chapman et al., 2011). In
other tumors, however, including those with mutant RAS, RAF
inhibitors transactivate RAF dimers and stimulate ERK signaling.
In contrast, allosteric MEK inhibitors suppress ERK signaling
in all normal and tumor cells (Pratilas et al., 2008; Solit et al.,
2006). Yet, whereas MEK inhibitors have significant antitumor
activity in BRAFV600E tumors (Flaherty et al., 2012), their effec-
tiveness is marginal in tumors with KRAS mutations. We have
now investigated the basis for this genotype-specific differential
sensitivity.
RESULTS
KRAS Mutant Tumors Are Less Sensitive to MEK
Inhibitors Than Are BRAF Mutant Tumors
We examined the Genomics of Drug Sensitivity in Cancer
(GDSC) data set (Yang et al., 2013) to correlate the sensitivity
of tumor cells to MEK inhibitors with cancer genotype. The
mean IC50s for three such compounds, i.e., selumetinib,
RDEA119, and PD0325901, were compared in tumors
harboring BRAF or RAS mutations and those with wild-type al-
leles for these genes. Tumors of various lineages were included
in this analysis. Sensitivity to MEK inhibition was correlated with
the presence of oncogenic mutations and with the particular
oncoprotein responsible for activating the pathway (Figure S1A
available online; see below). The mean IC50 for each compound
was higher in KRAS mutant tumors than in BRAF mutant
tumors, whereas NRAS mutant tumors had an intermediate
sensitivity.
In order to investigate the reason for the reduced sensitivity of
KRAS mutant tumors to MEK inhibitors, we first confirmed the
mutation-dependent sensitivity to PD0325901 in a group of mel-
anoma (M) and lung (L) cancer cell lines harboring BRAFV600E
(A375M, MV522L, and HCC364L) or KRASG12C/S (H358L, A549L,
andH2030L)mutations. As predicted, the latter were significantly
less sensitive than were the former (Figure 1A). Three hours after
treatment, 40–50 nMPD0325901 was found to inhibit ERK phos-
phorylation more than 95%, both in KRAS and BRAF mutant tu-
mors (Figure 1B and S1B). We used this dose to ask whether the
difference in sensitivity between the genotypes was associated
with a difference in the durability of inhibition of ERK signaling
over time. In KRAS mutant lung cancer cell lines prolonged
PD0325901 exposure was unable to produce sustained ERK
inhibition as indicated by a rebound in ERK phosphorylation af-
ter 24–48 hr (Figure 1C). The magnitude of this rebound ranged
from 25% to 75% of the pre-treatment ERK phosphorylation
(Figure 1D) and also occurred in KRASmutant pancreatic cancer
cells (Figure S1B). In contrast, much less pERK rebound was
observed in BRAFV600E cell lines (Figures 1C and 1D). These
data imply that the reduced efficacy of PD0325901 in KRAS
mutant cancers may result from an inability to sustain pathway
inhibition.698 Cancer Cell 25, 697–710, May 12, 2014 ª2014 Elsevier Inc.CRAF Knockdown Enhances the Antiproliferative Effect
of MEK Inhibition in KRAS Mutant Tumors
The difference in sensitivity between BRAF and KRAS mutant
tumors may reflect the fact that MEK is the major substrate of
mutant BRAF, whereas mutant KRAS signals through multiple
effectors. We hypothesized that the ability of MEK inhibitors
to inhibit the proliferation of KRAS mutant cells would be
augmented by concurrent targeting of other RAS-effector path-
ways. To address this possibility in a nonbiased way, we per-
formed a small hairpin RNA (shRNA) screen to identify genes
whose inhibition sensitize mutant KRAS tumors to PD0325901
inhibition using a well-characterized genetic model of mutant
KRAS-induced pancreatic cancer. In order to develop a system
in which shRNA expression is conditionally induced by tetracy-
cline, we engineered a ‘‘TET-ON’’ competent murine pancreatic
cancer cell line using pancreatic progenitor cells isolated from
a murine fetus harboring an endogenous KrasG12D mutation.
These cells were engineered to express c-Myc and a potent
p53-specific shRNA, linked to a reverse tet transactivator (Fig-
ures S1C–S1E). Orthotopic injection of these cells into the
pancreas of a recipient mouse resulted in a tumor that displayed
key histological characteristics of human pancreatic cancer
(Figure S1F). A cell line derived from such tumors, referred to
as KRPC, was dependent on KRAS (data not shown) and
capable of inducible shRNA expression. KRPC cells also ex-
hibited rebound ERK phosphorylation after treatment with
PD0325901 (Figure S1G), similar to that in human KRAS mutant
lung and pancreatic cancer cell lines.
KRPC cells were transduced with a doxycycline (dox)-induc-
ible shRNA library containing a panel of reporter-validated
shRNAs (Fellmann et al., 2011; Zuber et al., 2011) that target
70 genes encoding various components of RAS effector path-
ways. Dox-induction of shRNA expression was followed by
treatment with either DMSO or PD0325901 in order to identify
shRNAs that were selectively depleted after 10 days of MEK in-
hibitor treatment (Figures 1E, 1F, and S1H). PD0325901 was
chosen because it had the highest potency of the drugs in Fig-
ure S1A. Positive control shRNAs, targeting an essential gene
(Rpa3), were strongly depleted in both vehicle and drug-treated
cells. Consistent with the importance of mutant KRAS in cancer
maintenance, shRNAs targeting KRAS were also depleted from
the population regardless of drug treatment (Figures 1E and
1F). By contrast, CRAF-specific shRNAs were depleted by
over 6-fold after MEK inhibitor treatment (Figure 1F) but were
only minimally depleted after treatment with DMSO (Figures 1E
and S1I). One of three BRAF-specific shRNAs was marginally
depleted with PD0325901, whereas shRNAs targeting ARAF or
other RAS effectors were not selectively depleted after MEK in-
hibitor treatment (Figure S1J). In an independent screen with an
shRNA library enriched for known drug targets, CRAF knock-
down was again the most significant enhancer of MEK inhibition
in KRAS mutant cells (data not shown).
To confirm these findings, we tested a series of CRAF- and
BRAF-specific shRNAs in this pancreatic cancer model and in
human KRAS mutant cancer cell lines. Four different CRAF
shRNAs that effectively decreased CRAF expression (Figure 1G)
were not depleted when used alone but were selectively
depleted in tumor cells exposed to PD0325901 (Figure 1H).
The two effective BRAF shRNAs tested were also depleted after
Figure 1. KRAS Mutant Tumors Are Less Sensitive to Allosteric MEK Inhibitors Than Are BRAFV600E Tumors
(A) BRAFV600E and KRAS mutant tumor cell lines were treated with increasing doses of PD0325901 for 3 days to determine the effect on proliferation. A
representative example of three independent experiments (each performed in triplicate) is shown as means ± SEM.
(B–D) The indicated tumor cell lines were treated with increasing amounts of PD0325901 for 3 hr (B) or with 50 nM of PD0325901 for the indicated times (C).
Lysates were assayed by immunoblotting to determine the level of MEK and ERK phosphorylation. The bands were quantified by densitometry, and the pERK
level after treatment was normalized to the pre-treatment pERK level (D). A representative example of three independent experiments for each cell line is shown.
(E and F) Fold change in shRNA abundance in DMSO-treated (E) or PD0325901-treated (F) cells. Note the selective depletion in shRNAs targeting CRAF with
PD0325901 treatment. shRNAs targeting Rpa3 or KRAS were used as positive controls, whereas those targeting luciferase or renilla were used as negative
controls. Bars represent the mean fold change from an experiment performed in triplicate.
(G) KRPC cells were transduced with the indicated CRAF shRNAs, and lysates were subjected to immunoblotting to determine the knockdown in CRAF
expression.
(H) KRPC cells infected with four different CRAF shRNAs were treated with dox to induce CRAF knockdown and PD0325901 (+MEK inhibitor) or DMSO (MEK
inhibitor) for the indicated times. The data were normalized to the shRNA abundance in cells after 48 hr of treatment with dox.
(I) KRPC cells were stably infected with the indicated dox-inducible CRAF shRNA, followed by implantation in athymic mice. The mice were treated with MEK
inhibitor PD0325901 in the presence or absence of dox. The effect of CRAF knockdown (+dox) on the ability of the MEK inhibitor to inhibit KRAS tumor growth is
represented as mean ± SEM (n = 6).
See also Figure S1.
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Effective MEK Inhibition in KRAS Mutant TumorsPD0325901 treatment, but to a lesser extent (Figures S1K and
S1L). In human KRAS mutant pancreatic cancer cells, CRAF
shRNAs were also depleted only after MEK inhibitor treatment
(Figures S1M and S1N). In this experiment, BRAF-specific
shRNAswere also depleted, but to a lesser extent. Similar results
were observed following PD0325901 treatment of KRPC xeno-
grafts harboring a tet-responsive CRAF shRNA: when CRAF
expression was knockdown in combination with PD0325901,
there was a significantly greater tumor regression than that
observed when PD0325901 was administered alone (Figure 1I).
These results show that CRAF inhibition is required for
PD0325901 to be effective against KRAS mutant cancers andsuggest that inhibitors like PD0325901 are less effective at inhib-
iting CRAF-activated MEK.
The Rebound in ERK Phosphorylation Is Dependent on
CRAF
To directly test whether RAF family members contribute to the
rebound in ERK phosphorylation observed after MEK inhibitor
treatment, we knocked down RAF in KRASmutant lung cancers.
CRAF small interfering RNAs (siRNAs) decreased pMEK levels
and attenuated the rebound in ERK phosphorylation at 48 hr,
whereas control siRNAs had no effect (Figures 2A, S2A, and
S2B). Knockdown of BRAF had a small effect on the reboundCancer Cell 25, 697–710, May 12, 2014 ª2014 Elsevier Inc. 699
Figure 2. CRAF Expression Attenuates the Effects of MEK Inhibition in KRAS Mutant Tumors
(A) KRAS mutant lung cancer cells (A549) were transfected with siRNA pools targeting each of the RAF isoforms and then treated with 50 nM of PD0325901 for
48 hr.Whole-cell lysateswere evaluated by immunoblotting to determine the effect on ERK signaling. A representative example of three independent experiments
for each siRNA is shown.
(B) The indicated cell lines were treated with 50 nM of PD0325901 as shown. CRAF was immunoprecipitated from whole-cell lysates and subjected to a kinase
assay using an inactive MEK1 (K97R, KD) as the substrate. CRAF activity was determined by immunubloting with a phospho-MEK antibody. A representative
example of two or more independent experiments for each cell line is shown.
(C) Craf/ MEFs were cotransfected with the indicated constructs and then treated with PD0325901 for 1 hr. Lysates were analyzed by immunobloting to
determine ERK phosphorylation. A representative example of two independent experiments for each RAS isoform is shown. WT, wild-type; KD, kinase dead.
See also Figure S2.
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Effective MEK Inhibition in KRAS Mutant Tumorsin cells with mutant RAS, whereas knockdown of ARAF expres-
sion had no effect (Figure 2A). CRAF expression was also
required for the rebound observed in KRPC cells treated with
PD0325901 (Figure S2C). Although these data do not exclude
a potential role for wild-type BRAF in mediating the rebound in
ERK phosphorylation in KRAS mutant cells, they suggest that
CRAF is required for the pERK rebound and are consistent
with reports that CRAF is the main RAF isoform responsible for
driving ERK signaling in some RAS mutant tumors (Blasco
et al., 2011; Dumaz et al., 2006; Karreth et al., 2011).
The pERK rebound observed in KRAS mutant tumors was
associated with induction of pMEK (Figure 1C) and induction of
CRAF phosphorylation at Ser 338 (Figure S2D). The rebounds
in pMEK and pERK are not linearly related, probably because
the level of ERK phosphorylation is due to changes in MEK
kinase activity and the activity and expression of ERK phospha-
tases. Induction of MEK phosphorylation in cells exposed
to MEK inhibitors results from inhibition of ERK-dependent
inhibitory phosphorylations of CRAF, with attendant activation
of CRAF kinase (Alessi et al., 1994; Dougherty et al., 2005). By
contrast, and in agreement with previous data (Pratilas et al.,
2009), the level of MEK phosphorylation decreased slightly after
treatment in BRAFV600E tumors (Figure 1C). The selective induc-
tion of MEK phosphorylation suggests that CRAF activation
occurs differentially in tumors with mutant RAS compared to
those with mutant BRAFV600E.
In order to assay the induction of CRAF kinase activity, we
performed in vitro kinase reactions, with CRAF that was immu-
noprecipitated from cells treated with a MEK inhibitor and a
kinase-dead recombinant MEK1 as a substrate. In agreement700 Cancer Cell 25, 697–710, May 12, 2014 ª2014 Elsevier Inc.with the conclusion above, PD0325901 treatment increased
CRAF activity over time in KRAS mutant models, whereas only
a small induction was noted in BRAFV600E cells (Figures 2B and
S2E). Thus, compared to cells harboring BRAFV600E, KRAS
mutant cells have more pronounced reactivation of CRAF after
inhibition of ERK signaling, which in turn mediates the rebound
in ERK phosphorylation.
MEK Is Less Susceptible to Inhibition when Activated by
CRAF Than by BRAFV600E
Because RAS activation and CRAF activity are both low in
BRAFV600E tumors, in which MEK/ERK signaling is driven almost
entirely by BRAFV600E (Wan et al., 2004), we hypothesized that
the decreased MEK inhibitor sensitivity of KRAS tumors is due
to ineffective inhibition of CRAF-driven MEK signaling by these
drugs. To test this, we undertook two experimental approaches.
In the first approach, mutant KRAS was coexpressed with either
wild-type (WT) CRAF or kinase-dead (KD, i.e., K375M) CRAF in
Craf/ mouse embryonic fibroblasts (MEFs). As expected,
1 hr treatment with PD0325901 inhibited ERK phosphorylation
in cells expressing the CRAFKD. In those expressing CRAFWT,
however, the pathway sensitivity to the drug was significantly
reduced (Figure 2C). A similar effect was observed when ERK
signaling was driven by active NRAS (Figure 2C). These results
validate our CRAF knockdown findings and strengthen our
conclusion that CRAF activation reduces the efficacy of MEK
inhibitor treatment.
In the second approach, we developed a cellular system in
which ERK signaling could be selectively switched from being
driven by BRAFV600E to being driven by CRAF. To accomplish
Figure 3. MEK Is Less Susceptible to Inhibition when Activated by CRAF Than by BRAF V600E
(A) A schematic representation of the experimental system used. BRAFV600Emutant A375 cells have low levels of CRAF activity at baseline, andMEK activation is
dependent on BRAF kinase. Treatment with RAF or MEK inhibitors inhibits ERK signaling in these cells. We relied on the ability of RAF inhibitors to transactivate
RAF dimers in order to switch from BRAFV600E-dependent to catC-dependent signaling. To this end, catC was expressed to form BRAFV600E-catC heterodimers
in A375 cells. A gatekeeper mutation in catC (T421M) prevents RAF inhibitor binding. Thus, the RAF inhibitor vemurafenib binds to and inhibits BRAFV600E while
transactivating catC in heterodimers. A kinase-dead catC (T421M/K375M) was used as a control.
(B) A375 cells expressing the indicated constructs were treated with increasing doses of vemurafenib for 1 hr, and whole-cell lysates were subjected to
immunoblotting with the indicated antibodies.
(C) A375 cells were transfected with increasing amounts of plasmid encoding catCT421M. In the indicated rows, RAF inhibitor pretreatment (vemurafenib, 1 mM,
1 hr) was used to transactivate catC in heterodimers and switch fromBRAFV600E- to catC-driven signaling. Following transfection and pretreatment as shown, the
cells were treated with increasing doses of PD0325901 for 1 hr to determine the drug’s ability to inhibit ERK phosphorylation. A representative example of at least
two independent experiments for each condition is shown.
(D and E) The bands in (C) were quantified by densitometry and normalized to the level of pERK prior to PD0325901 treatment.
See also Figure S3.
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Effective MEK Inhibition in KRAS Mutant Tumorsthis, we took advantage of the ability of RAF inhibitors to trans-
activate RAF dimers (Figure 3A). We utilized the BRAFV600E cell
line A375, where CRAF activity is low and MEK activation is
BRAFV600E dependent (Lito et al., 2012; Pratilas et al., 2009).
Vemurafenib treatment inhibits BRAFV600E and ERK signaling in
these cells (Figure 3B, vector). An N-terminal truncated CRAF
(catC) was expressed in A375 to form intracellular BRAFV600E-
catC heterodimers. CatC dimerizes in a RAS-independent
manner and is transactivated by RAF inhibitor vemurafenib (Pou-
likakos et al., 2010). CatCwas engineered to harbor a gatekeeper
mutation (T421M) in order to prevent its binding to vemurafenib.
Thus, when vemureafenib binds to and inhibits BRAFV600E, it
transactivates catCT421M in heterodimers, thereby triggering a
switch from BRAFV600E- to catC-dependent MEK activation (Fig-
ure 3A). A kinase-dead catCT421M/K375Mwas used as a control. Asshown in Figure 3B, expression of catCT421M rendered ERK
signaling insensitive to vemurafenib, because this drug does
not inhibit RAF dimers (lanes 1–4), whereas ERK signaling was
sensitive to vemurafenib in cells expressing catCT421M/K375M
(compare lanes 7 and 8 to 3 and 4). The residual signaling in lanes
3 and 4 is therefore due to transactivation of catCT421M by vemur-
afenib and represents activation ofCRAF kinase-dependent ERK
signaling. Vemurafenib treatment induced similar effects even
when lower amounts of catCwere expressed (FiguresS3A–S3C).
We then determined whether the MEK inhibitor PD0325901
could effectively inhibit vemurafenib-induced catC-dependent
ERK signaling (i.e., CRAF-dependent signaling). The inhibition
of ERK phosphorylation in response to the MEK inhibitor
PD0325901 was similar in BRAFV600E cells transfected with
an empty vector or with catCT421M/K375M (Figure 3C, rows 1Cancer Cell 25, 697–710, May 12, 2014 ª2014 Elsevier Inc. 701
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Effective MEK Inhibition in KRAS Mutant Tumorsand 2), situations in which ERK phosphorylation is driven by
BRAFV600E. In contrast, expression of kinase active catCT421M
attenuated the ability of PD0325901 to inhibit ERK phosphoryla-
tion (Figure 3C, rows 3–6) in a manner that was proportional to
the level of catC expression (Figure 3D). Cells expressing low
catC levels showed no change in their sensitivity to MEK inhibi-
tors in the absence of vemurafenib (Figure 3C, rows 3 and 4). In
these cells, however, vemurafenib treatment induced appre-
ciable CRAF kinase signaling (Figures S3B and S3C), and this
was sufficient to reduce the sensitivity of pERK to PD0325901
(Figure 3C, rows 7 versus 3 or 8 versus 4; Figure 3E). In cells in
which catC expression was high enough to drive CRAF kinase-
dependent signaling in the absence of vemurafenib, the effects
of PD0325901 were attenuated regardless of whether the cells
were treated with vemurafenib (Figure 3C, rows 5 and 6 versus
9 and 10). These data show that ERK signaling activated by
CRAF is less sensitive to PD0325901 than when activated by
BRAF V600E.
MEK Inhibitors Induce RAF-MEK Complexes
In unpublished data (E.J. and P.L), we observed that some MEK
inhibitors induce the association of MEK with RAF. We hypothe-
sized that MEK bound to an activated RAF kinase is less sensi-
tive to MEK inhibitors than is unbound MEK. We first evaluated
if PD0325901 or selumetinib induced RAF/MEK complexes in
HEK293 cells engineered to express FLAG-MEK1. Exposure of
these cells to either drug increased the interaction of each RAF
kinase with FLAG-MEK1 (Figure 4A). We next tested whether in-
duction of these complexes differed between cells with mutant
BRAF or mutant KRAS. Treatment of KRAS mutant A549 cells
with PD0325901 increased the association of endogenous
MEK1 with all three RAF kinases (Figure 4B and 4C). In contrast,
the same treatment did not induce MEK-RAF complexes in
BRAFV600E A375 cells (Figure 4C). In this setting, PD0325901
reduced the level of MEK1 in complex with BRAF, as well as
the level of MEK phosphorylation.
In order to confirm that the differences described above were
related to the oncoprotein responsible for activating ERK
signaling, we repeated the experiments in HEK293 cells that ex-
press FLAG-MEK1 and either KRASG12V or BRAFV600E. Induction
of MEK1-RAF complexes by PD0325901 was only observed
when MEK1 was coexpressed with KRASG12V (Figure S4A,
lanes 1 and 2). In contrast, when MEK1 was coexpressed with
BRAFV600E, there was a decrease in MEK1-RAF complexes after
3 hr of treatment (Figure S4A, lanes 5 and 6). Similar findings
were observed when KRAS or BRAF mutants were coexpressed
with MEK2 (Figure S4B). The data suggest that binding of MEK
to allosteric inhibitors causes MEK to bind to RAF in cells with
mutant RAS, but not in those with BRAFV600E.
The Effect of MEK Inhibitors Is Enhanced when RAF-
MEK Interactions Are Impaired
These findings suggest the possibility thatMEK bound to an acti-
vated CRAF in tumors with activated RAS is less sensitive to
MEK inhibitors than is free MEK. We therefore tested whether
reducing the affinity of MEK for RAFwould enhance its sensitivity
to drugs in cells with activated CRAF. The proline-rich region of
MEK1 is thought to mediate its interaction with RAF (Dang et al.,
1998). Alanine substitutions of Met 308 and Ile 310 impair this702 Cancer Cell 25, 697–710, May 12, 2014 ª2014 Elsevier Inc.interaction (McKay et al., 2009) and, in our experiments, pro-
duced a MEK1 mutant (impaired RAF interaction, IRI) that was
defective in its ability to bind RAF kinases (Figure 4D). We used
the system illustrated in Figure 3 to test if altering the RAF-
MEK interaction affects the inhibition of CRAF-induced ERK
signaling by these drugs. In cells in which catC was coexpressed
with FLAG-MEK1, there was residual pERK following treatment
with PD0325901, selumetinib, or RDEA119 (Figure 4E). When
catC was coexpressed with MEK1IRI instead, these drugs in-
hibited ERK phosphorylation more effectively (Figures 4E, S4C,
and S4D). These findings suggest that MEK bound to activated
CRAF is less sensitive to inhibition by MEK inhibitors like
PD0325901. Together, our data support the conclusion that
MEK inhibitors activate CRAF by relieving ERK-dependent nega-
tive feedback and also cause formation of a CRAF-MEK com-
plex. These two effects cooperate to attenuate inhibition of
MEK in KRAS mutant tumors (Figure 4F).
Trametinib and CH5126766 Inhibit ERK Signaling More
Durably Than PD0325901
Trametinib and CH5126766 are newer MEK inhibitors that have
been reported to inhibit the proliferation of selected RAS mutant
xenografts better than PD0325901 does (Gilmartin et al., 2011;
Ishii et al., 2013). On average, trametinib inhibited the prolifera-
tion of BRAFV600E and KRAS mutant cancer cell lines with lower
IC50s than did PD0325901 or selumetinib (Figures 5A and S5A),
even though trametinib and PD0325901 had similar potencies
against MEK1 in vitro (Figure S5B). When compared to
PD0325901, CH5126766 was less potent at inhibiting MEK1
kinase activity in vitro. CH5126766, inhibited the proliferation of
BRAFV600E and KRAS mutant cell lines at a similar IC50 range
(Figure 5A), although CH5126766 was still less effective against
some KRAS mutant cells (Figure S5A, H2030 and A549).
Increasing concentrations of PD0325901 did not reduce the
rebound in ERK phosphorylation occurring in KRAS mutant
A549 cells at 48 hr (Figure 5B). In contrast, the rebound associ-
ated with trametinib or CH5126766 decreased with increasing
concentrations of these drugs (Figure 5B). As these drugs have
different potencies for MEK1 in vitro (Figure S5B), we also eval-
uated the effects of each drug at concentrations 50 times higher
than their IC50 for kinase inhibition in vitro. As compared to
PD0325901, treatment with trametinib or CH5126766 for 48 hr
at these concentrations resulted in more sustained inhibition
of pERK in KRAS mutant cells (Figure S5C; H2030) and also
in A375 cells expressing increasing amounts of active CRAF
(Figure S5D).
If CRAF knockdown enhances the effect of MEK inhibitors by
more durably inhibiting ERK phosphorylation, then its effect
should be minimized when combined with trametinib (which
inhibits ERK signaling better than PD0325901). To test this,
we evaluated whether cells expressing CRAF shRNAs were
depleted when trametinib was administered at two different
doses: one associated with pERK rebound (4 nM) and a higher
dose associated with much less rebound (40 nM). As shown in
Figure 5C, cells expressing CRAF shRNAs were selectively
depleted following treatment with 4 nM trametinib, but not
following treatment with 40 nM trametinib. By contrast, a higher
dose of PD0325901 did not affect the selective depletion of
cells expressing CRAF shRNA (Figure 5D). A similar effect was
Figure 4. Allosteric MEK Inhibitors Induce RAF-MEK Complex Formation in KRAS Mutant Tumors
(A) HEK293 cells were transfected with FLAG-MEK1, followed by treatment with PD0325901 for 3 hr. MEK1 was immunoprecipitated using an anti-FLAG
antibody, followed by immunoblotting with the indicated antibodies to determine RAF-MEK interactions. A representative example of at least two independent
experiments with each drug is shown.
(B) Whole-cell lysates from A375 cells were subjected to immunoprecipitation with immunoglobulin G or a MEK1 antibody and then immunoblotted for the
indicated proteins. Two MEK-specific IP replicates are shown.
(C) Cells were treated with PD0325901 for 3 hr, and endogenous MEK1 was immunoprecipitated to determine its interaction with RAF kinases. A representative
example of three independent experiments is shown.
(D) HEK293 cells were transfected with WT MEK1 or a MEK1 mutant with impaired RAF interaction (IRI, M308A/I310A). RAF-MEK1 complexes were determined
as in (C).
(E) A375 cells were transfected with the indicated constructs and then treated with PD0325901 (50 nM), selumetinib (500 nM), or RDEA119 (100 nM) for 1 hr to
determine the effect on ERK phosphorylation. A representative example of at least two independent experiments for PD0325901 and selumetinib are shown.
(F) A schematic diagram modeling the role of CRAF in the differential adaptation of KRAS and BRAF mutant tumors to MEK inhibitor treatment.
See also Figure S4.
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Effective MEK Inhibition in KRAS Mutant Tumorsobserved with CH5126766 (data not shown). These data support
our model that PD0325901 does not sufficiently inhibit CRAF-
driven ERK signaling and that CRAF knockdown enhances the
effects of MEK inhibitors because the combination produces
sustained ERK inhibition.
If the added benefit of trametinib occurs because of better
inhibition of CRAF-driven signaling than PD0325901 does, then
the combination of PD0325901 with a CRAF inhibitor ought to
yield a similar response to that of trametinib alone. To test this,
we used AZ628, which has been characterized as an irreversible
CRAF inhibitor, although it also targets other RAF kinases. As
shown in Figure 5E, treatment with PD0325901 or AZ628 alonedid not cause significant growth inhibition in KRAS mutant
A549 cells. Combined PD0325901 andAZ628 treatment, howev-
er, was not only much more effective than either drug alone but
also produced a similar growth inhibition as observed with tra-
metinib treatment alone (Figure 5E).
Trametinib Decreases the Interaction of MEK1with RAF
Kinases
We then asked whether the newer MEK inhibitors have a
different effect on the formation of RAF-MEK complexes or
MEK phosphorylation. In contrast to PD0325901, trametinib
did not induce a significant interaction between MEK1 andCancer Cell 25, 697–710, May 12, 2014 ª2014 Elsevier Inc. 703
Figure 5. Newer Allosteric MEK Inhibitors Inhibit ERK Phosphorylation Better Than PD0325901
(A) A panel of BRAFV600E (n, 15) and KRAS mutant (n, 50) tumor cell lines was subjected to proliferation assays with the indicated drugs. Cells were treated for
3 days with increasing amounts of the indicated compounds, in order to determine their respective IC50s. Themean (line) and range of IC50s across cell lines (n of 3
for each cell line) is shown.
(B) KRAS mutant A549 cells were treated with increasing concentrations of PD0325901, trametinib, or CH5126766 for 48 hr. Lysates were evaluated by
immunoblotting to determine the level of ERK phosphorylation. A representative of two independent experiments is shown.
(C and D) KRPC cells expressing dox-inducible CRAF shRNAs were treated with dox alone (no drug) or in combination with trametinib (C) or PD0325901 (D) at the
indicated concentrations. The data were normalized to the number of shRNA-expressing cells in the dox-only controls. A representative of two independent
experiments with at least two different shRNAs targeting CRAF is shown.
(E) KRAS mutant A549 cells were treated with 100 nM PD0325901, 2 mM AZ628, or 100 nM trametinib as indicated. The fold increase in viable cell number over
time is shown. Means ± SEM from a representative of two independent experiments, each performed in triplicate, are shown.
See also Figure S5.
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expressed alone (Figure 6A) or coexpressed with mutant KRAS
or BRAFV600E (Figure S4A). Similar effects were observed when
MEK2 was expressed with KRAS or BRAF (Figure S4B). More-
over, trametinib treatment diminished the ability of endogenous
MEK1 to interact with RAF kinases in both BRAFV600E (Figure 6B)
and KRAS mutant cells (Figure 6C). In KRAS mutant cells, this
effect persisted up to 48 hr after drug treatment (Figure 6D).
Surface plasmon resonance (SPR) was used to determine if
the change in complex formation reflected a change in the af-
finity of MEK for RAF. Purified BRAF or CRAF were immobilized
on a sensor chip followed by sequential injections of increasing
amounts of MEK1. These experiments were performed in
the presence of 500 mM ATP and before or after addition of
trametinib at a saturating concentration of 3 mM (Figure 6E).704 Cancer Cell 25, 697–710, May 12, 2014 ª2014 Elsevier Inc.When bound to trametinib, the dissociation constants for the
interaction of MEK1 with either BRAF or CRAF kinase were
0.101 and 0.107 mM, respectively. By comparison, the dissoci-
ation constants for MEK1 unbound to drug were 0.055 and
0.038 mM, respectively. Thus, trametinib is a MEK inhibitor
that reduces the affinity of MEK from RAF, thereby reducing
steady-state levels of RAF-MEK complexes. Trametinib inhibits
the catalytic activity of MEK by the same mechanism as
PD0325901, yet it has the opposite effect on the interaction
of MEK with the RAF kinases. In contrast to the effect observed
with PD0325901, trametinib decreased the rebound in ERK
phosphorylation in tumor cells with mutant KRAS (Figure 5B).
This supports our above finding that CRAF-MEK complexes
reduce the ability of PD0325901-like inhibitors to inhibit ERK
signaling.
Figure 6. Trametinib Binding Weakens the Interaction of MEK1 with RAF
(A) HEK293 cells were transfected with FLAG-MEK1 and then treated with PD0325901 (50 nM), trametinib (10 nM), or CH5126766 (250 nM) for 3 hr. MEK1 was
immunoprecipitated with a FLAG antibody, and RAF-MEK complexes were determined by immunoblotting.
(B and C) BRAFV600E (A375; B) and KRASG12S (A549; C) cells were treated with the indicated MEK inhibitors as in (A). Lysates were subjected to immunopre-
cipitations and immunoblotting to determine the interaction between endogenous MEK1 and RAF kinases.
(D) A549 cells were treated with PD0325901 (50 nM) or trametinib (10 nM) for the indicated times. RAF-MEK complexes were determined as in (C).
(E) Recombinant GST-BRAF or GST-CRAF was immobilized on a sensor chip, followed by sequential injections of increasing amounts of His-MEK1 in the
presence or absence of trametinib at a saturating concentration (3 mM) to determine the association and dissociation rates of MEK-RAF complexes. A repre-
sentative of at least two independent experiments is shown in each panel of this figure.
(F) Effect of MEK inhibitors on the binding constants for the interaction between MEK1 and RAF.
See also Figure S6.
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Induces RAF-MEK Complexes
In contrast to trametinib, CH5126766 promoted the formation of
RAF-MEK complexes (Figures 6A–6C; Figures S4A and S4B). In
addition, CH5126766 completely prevented the induction of
MEK phosphorylation in KRAS mutant tumor cells (Figure S6).
These results are consistent with our previous findings that
CH5126766 blocks MEK phosphorylation and that CH5126766-
bound MEK1 has a markedly slower dissociation from RAF ki-
nases (Ishii et al., 2013).
The ability of CH5126766 to prevent MEK phosphorylation,
while inducing RAF-MEK complexes, demonstrates anothermechanism for effectively inhibiting ERK signaling in KRAS
mutant tumors. To investigate the structural basis for this mech-
anism, we determined the ternary complex of MEK1 bound to
CH5126766 and an ATP analog at a resolution of 2.7 A˚ (Fig-
ure 7A; Table S1). CH5126766 interacts with a binding pocket
defined by the MEK1 activation segment, catalytic loop, and
ATP-binding site. MEK1 bound to CH5126766 was in a cata-
lytically inactive conformation, with an outwardly shifted aC
helix. CH5126766 formed a critical hydrogen bond with the
backbone amide of Ser 212, in a similar manner as other MEK
inhibitors, including PD03259021 (Figure S7A). This hydrogen
bond is critical for the binding of allosteric inhibitors to MEKCancer Cell 25, 697–710, May 12, 2014 ª2014 Elsevier Inc. 705
Figure 7. Interaction with Ser 222 and Allosteric Displacement of the MEK Activation Segment by CH5126766 Prevents RAF-Mediated
Phosphorylation
(A) The ternary structure of MEK1 bound to CH5126766 and an ATP analog at a resolution of 2.7 A˚. Its interaction with the MEK activation segment residues Ser
212, Asn 221, and Ser 222 are shown.
(B) Superpositioning of CH5126766 (green), CH4987655 (yellow), and PD0325089 (an enantiomer of PD0325901, red) and their effect on the orientation of the
MEK1 activation segment.
(C–E) Interactions of the indicated compounds with key residues in the MEK1 activation segment.
(F) KRAS mutant A549 cells were treated with the indicated inhibitors for 3 hr, and whole-cell lysates were subjected to immunoblotting with the indicated
antibodies. A representative example of three independent experiments is shown.
(G) HEK293 cells transfected with wild-type MEK1 or a MEK1mutant harboring phosphomimetic substitutions with glutamic acid at Ser 218 and Ser 222 (i.e., EE)
were treated with CH5126766 for 3 hr. Coimmunoprecipitations were used to determine the interaction between FLAG-tagged MEK1 and endogenous BRAF or
CRAF. A representative example of two independent experiments is shown.
(H) Schematic diagram representing the allosteric effects induced by each MEK inhibitor.
See also Figure S7 and Table S1.
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drugs.
Compared to other inhibitors, the distinct feature of
CH5126766 binding was its extension along the activation
segment of MEK1 (Figures 7A and 7B) and its interaction with
Asn 221 and Ser 222 (Figure 7C), with the latter interaction being
coordinated by a water molecule. CH5126766-boundMEK1 dis-
played a lateral displacement of the activation segment, causing
a minor and a major repositioning of the RAF phosphorylation
residues Ser 218 and Ser 222, respectively (Figures 7B, 7C,
and S7B). This displacement was minimal in MEK1 bound to
an enantiomer of PD0325901 (Figures 7B, 7D, and S7C). Thus,
it is likely that CH5126766 prevents the phosphorylation of
MEK by binding to Ser 222, a key RAF phosphorylation site,
and by displacing the activation segment of MEK.
TheMEK inhibitor CH4987655 is similar to CH5126766 in that it
also interacts with Asn 221 and laterally displaces the activa-
tion segment of MEK (Figures 7B and 7E). Compared to
CH5126766, however, CH4987655 spans a shorter distance
along the MEK activation segment (Figure 7B) and does not
interact with Ser 222 (Figures 7E versus 7C). With these differ-
ences in mind, we tested the ability of CH4987655 to induce
MEK phosphorylation following MEK inhibitor treatment in KRAS
mutant A549 cells. CH4987655 caused a very minimal induction
of pMEK, compared to standard MEK inhibitors like PD0325901
(Figure 7F). MEK phosphorylation in CH4987655-treated cells,
however,wasmuchgreater than that inCH5126766-treatedcells,
suggesting that both lateral displacement of the activation
segment and Ser 222 binding are required for maximal inhibition
of MEK phosphorylation by allosteric compounds.
We thenaskedwhether the increase inMEK-RAFcomplexes in
cells treated with CH5126766 is caused by dephosphorylation of
MEK. A MEK1 mutant with phosphomimetic glutamate substitu-
tions at the RAF phosphorylation sites (i.e., S218E and S222E or
EE) was used to answer this question. As expected, CH5126766
treatment induced the interaction of MEK1WT with BRAF and
CRAF (Figure 7G). This induction was abolished in cells express-
ing MEK1EE treated with CH5126766, which suggests that the
higher affinity of CH5126766-bound MEK1 from RAF kinases
occurs because MEK bound to this compound cannot be phos-
phorylated. Consequently, CH5126766 is more effective at pro-
ducing sustained inhibition of ERK phosphorylation than is
PD0325901, despite inducing RAF-MEK complexes.
DISCUSSION
Selective MEK inhibitors have marginal activity in patients whose
tumors harbor KRAS mutations. Our data suggest that reactiva-
tion of CRAF limits the ability of MEK inhibitors to inhibit ERK
signaling in KRAS mutant tumors. Knockdown of CRAF expres-
sion enhanced the effects of MEK inhibitors on signaling and on
theproliferationofKRAS tumors.CRAFknockdownmayenhance
the antitumor effects of MEK inhibition by inhibiting other targets
of RAF in addition to MEK (Blasco et al., 2011). Several findings
presented here, however, suggest that MEK inhibitors do not
effectively inhibit CRAF-driven ERK signaling: the rebound in
ERK phosphorylation in mutant KRAS tumors exposed to MEK
inhibitors was driven by CRAF, and CRAF expression reduced
the ability of these drugs to inhibit ERK signaling. Furthermore,when thepathwaywas inhibitedwith the stronger drug trametinib,
enhancement by CRAF knockdown was minimal.
Activated ERK feedback inhibits the RAF/MEK/ERK pathway
in cells with activated RAS by directly phosphorylating and inhib-
iting CRAF kinase activity (Dougherty et al., 2005). MEK inhibitors
relieve this feedback by inhibiting ERK and dephosphorylating
and reactivating CRAF. This causes induction of MEK phosphor-
ylation in most tumor cells, including those with mutant KRAS
(Alessi et al., 1994; Dougherty et al., 2005; Pratilas et al., 2009).
By contrast, RAS-GTP levels are very low in tumors with
BRAFV600E (Lito et al., 2012), and MEK inhibitors cause only
marginal induction of CRAF kinase activity and do not induce
MEK phosphorylation in these cells. As inhibition of cellular
ERK signaling by PD0325901 varied inversely with the level of
activated CRAF, the decreased effectiveness of MEK inhibitors
in mutant KRAS cells is likely due to the release of feedback
inhibition of CRAF kinase activity.
MEK inhibitors like PD0325901 and selumetinib also increase
the association of MEKwith RAF kinases. This occurs in cells ex-
pressing mutant KRAS, but not in those expressing mutant
BRAF. These data suggest that when MEK is bound to an acti-
vated CRAF, it is less sensitive toMEK inhibitors than is unbound
MEK. In support of this model, expression of a MEK mutant that
interacts more weakly with RAF resulted in better inhibition of
CRAF-dependent ERK signaling.
Near-complete inhibition of ERK signaling is required for RAF
inhibitors to cause tumor regression in BRAFV600E tumors (Bollag
et al., 2010). Such potent pathway inhibition is unlikely to be
achieved with PD0325901, solumetinib, or other standard MEK
inhibitors in tumors driven by mutant KRAS. Our model suggests
that ERK signaling in these tumors may be more effectively in-
hibited by compounds that not only inhibit the catalytic activity
of MEK but also reduce its reactivation by CRAF. Indeed, we
found two MEK inhibitors that display this property and produce
a more durable inhibition ERK signaling than does PD0325901.
Trametinib and CH5126766 bind to a similar pocket in MEK as
other MEK inhibitors and inhibit its catalytic activity allosterically.
These compounds, however, also reduce the activation of MEK
by RAF through two distinct mechanisms. Binding to trametinib
increases the dissociation rate ofMEK fromRAF and reduces the
intracellular level of RAF-MEK complexes. This reduces both the
induction of MEK phosphorylation and the rebound in ERK phos-
phorylation observed in KRAS mutant tumors. CH5126766
works by a different mechanism; it interacts with Ser 222 and
Asn 221 on MEK and prevents its phosphorylation by activated
CRAF. Drug-bound, dephosphorylated MEK binds more tightly
to RAF, and the level of MEK-RAF complexes is induced. How-
ever, because CH5126766-bound MEK cannot be phosphory-
lated and released from RAF, it becomes a dominant-negative
inhibitor of RAF (Ishii et al., 2013).
Based on computational modeling, others have proposed that
MEK inhibitors that prevent MEK phosphorylation do so by inter-
acting with Ser 212 (Hatzivassiliou et al., 2013). However, this
in silico modeling was based on a crystal structure with a limited
definition of the carboxy terminal portion of the MEK activation
segment, which does not include Asn 221 and Ser 222. Here,
we solved the ternary structure of CH5126766-bound MEK1
and show that CH5126766 forms multiple interactions with the
activation segment of MEK, binding not only to Ser 212 butCancer Cell 25, 697–710, May 12, 2014 ª2014 Elsevier Inc. 707
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segment of MEK1. We believe that this is the likely mechanism
by which it prevents the phosphorylation of MEK by RAF.
Our results demonstrate that the ability of MEK inhibitors
to inhibit MAPK activity and inhibit KRAS mutant cancer cells
vary as a function of the specific biochemical properties of the
drug-bound MEK complex. Differences in cellular responses to
these drugs reveal subtleties in the biochemical regulation of
the pathway, particularly the role of CRAF-MEK complex forma-
tion in rendering KRAS mutant cancers less sensitive to these
drugs. Rational drug discovery relies on lead optimization of
compounds based on their selectivity, potency, and pharmaco-
logic properties. Understanding the exact mechanism of drug
activity in the appropriate signaling context is imperative in order
to design more effective compounds. Here, we identify two
biochemical properties that, if optimized, will improve the effi-
cacy of MEK inhibitors: increasing the dissociation rate of MEK
from RAF and preventing MEK phosphorylation by reactivated
CRAF. If coupled with clinical trial designs aimed at improving
the therapeutic index of these drugs, e.g., pulsatile or intermit-
tent dosing schedules, these efforts are likely to maximize the
clinical benefit of MEK inhibitors in KRAS mutant tumors.
EXPERIMENTAL PROCEDURES
Compounds and Cell Culture
PD0325901 was synthesized in theMSKCCOrganic Synthesis Core Facility by
O. Ouerfelli. Trametinib and CH5126766 were obtained from GlaxoSmithKline
and Chugai Pharmaceuticals, respectively. All compounds were diluted in
DMSO for in vitro experiments. Craf/MEFs were kindly provided by M. Bac-
carini; HEK293 were from Invitrogen, whereas BRAF and KRAS mutant cell
lines were obtained from the American Type Culture Collection. Cell lines
were maintained in Dulbecco’s modified Eagle’s medium or RPMI supple-
mented with 10% fetal bovine serum, glutamine, and antibiotics.
Antibodies, Immunoblotting, and Immunoprecipitations
Antibodies detecting pMEK, pERK, pCRAF, MEK, ERK, and CRAF were
obtained from Cell Signaling. V5 and FLAG antibodies were from Invitrogen
and Sigma, respectively. Immunoblotting was performed as described
(Poulikakos et al., 2010). Exogenously expressed FLAG-MEK1 was immuno-
precipitated (IP) via a FLAG-specific antibody agarose conjugate (Sigma) in
accordance with the manufacturer’s recommendations. Endogenous MEK1
was immunoprecipitated with MEK1 612B12 antibody (Cell Signaling). In
both cases, IPs were carried out at 4C overnight.
Immunoprecipitation Kinase Assays
Immunoprecipitation kinase assays were performed as described (Poulikakos
et al., 2010). Briefly, cells were lysed in NP-40 lysis buffer supplemented with
phosphatase and protease inhibitors (Roche). IPs were carried out at 4C for
4 hr, and immunoprecipitated CRAF was subjected to a kinase assay with
kinase-dead MEK1 (Millipore). Kinase assays were conducted in the presence
of 100 mM ATP at 30C for 30 min. MEK phosphorylation was assayed by
immunoblotting with phospho-specific antibodies.
Plasmids and Transfections
MEK1-, KRas-, and NRas-encoding plasmids were obtained from Biomyx.
CRAF or MEK constructs harboring various mutations were generated by
site-directedmutagenesis (Agilent). DNA and siRNA transfections were carried
out by using lipofectamine 2000 and RNAiMAX reagents in accordance with
the manufacturer’s recommendations.
Animal Studies
Nu/nu athymic mice were obtained from the Harlan Laboratories and main-
tained in compliance with Institutional Animal Care and Use Committee708 Cancer Cell 25, 697–710, May 12, 2014 ª2014 Elsevier Inc.(IACUC) guidelines. Subcutaneous xenografts and tumor measurements
were performed as described (Lito et al., 2012). All studies were performed
in compliance with institutional guidelines under an IACUC-approved protocol
(Memorial Sloan-Kettering Cancer Center no. 09-05-009).
Surface Plasmon Resonance
Surface plasmon resonance was performed as described (Ishii et al., 2013).
Briefly N-terminal glutathione S-transferase (GST)-tagged BRAF or CRAF
was captured on the surface of a CM5 sensor chip (GE Healthcare) by anti-
GST polyclonal antibodies that were preimmobilized on the chip in accordance
with themanufacturer’s instructions. His6-MEK1 solutions at concentrations of
0.0256, 0.064, 0.16, 0.4, and 1 mmol/l were injected sequentially in order of
increasing concentration over the sensor chip in the absence or presence
of 3 mmol/l of the test compounds, and then the dissociation constants of
His6-MEK1 were calculated for the immobilized RAF for each condition in the
presence of 500 mmol/l ATP. The effects of MEK inhibitors on the RAF-MEK1
complex formation were determined by using single-cycle kinetics.
Crystallization and Structural Determination of MEK1-CH5126766
Complex
MEK1 kinase (residues 62–393, del 271–302) was expressed in Escherichia
coliwith a His tag. The expressed protein was purified using standard chroma-
tography. Crystals were obtained at 4C from sitting drops using a reservoir
solution (7.5%–10% PEG 8000, 0.2 M NaCl, 0.2 M Ammonium sulfate, and
0.1 M citrate buffer [pH 4.2]) by vapor diffusion. Diffraction data were collected
at 100 K at the SGX-CAT beamline in APX synchrotron using a Mar CCD de-
tector (Marresearch GmbH). The data set was processed with HKL2000 and
scaled with SCALA in the space group P3121. The structure of the MEK1
and CH5126766 complex was determined by molecular replacement. The
crystals contain onemonomer of the protein in the asymmetric unit. Themodel
was rebuilt manually in COOT and refined with CNX 2005 (Accelrys) to a final
resolution of 2.7 A˚. B-factors were refined isotropically. The final model con-
sisted of residues 62–380 with two breaks (residues 79–81; 268–307 were
disordered). The resulting electron density revealed an unambiguous binding
mode of CH5126766. For crystallographic data and refinement statistics,
see Table S1. This structure has been deposited in the Protein Data Bank
(PDB) with the ID code 3WIG.
Pooled Negative Selection Screening
A miR30-based shRNA library containing 193 shRNAs targeting 70 genes
encoding for various components of the Ras effector pathway was assembled.
All shRNAs included in this set were the top-scoring candidates in a fluores-
cence-activated cell sorting (FACS)-based high-throughput reporter assay
that functionally evaluates shRNA potency and thus leads to the identification
of highly potent shRNAs (Fellmann et al., 2011). The hairpin pool was subcl-
oned into TRMPV-Neo (Zuber et al., 2011) and combined with positive and
negative control shRNAs. Viral supernatant from triplicate transfections into
PlatE cells was harvested and used to transduce Tet-on KRPC cells under
conditions that led to single integrations (less that 5% initial infection rate).
Triplicates were processed separately throughout the screen, and at all times,
care was taken to maintain an shRNA representation exceeding 1,0003 per
replicate.
Successfully transduced cells underwent G418 selection (Invitrogen, final
concentration 500 mg/ml) for 7 days. At this time, T0 samples were obtained
for genomic DNA extraction, and the remaining cells were cultured in doxycy-
cline containing media (final concentration 1 mg/ml) to induce shRNA expres-
sion. At 48hr after dox treatment, cells of each triplicatewere furtherpropagated
in doxycycline containingmedia in the presence of 40 nMPD0325901or DMSO
for the duration of the screen. On the final day of the screen (Tf), approximately 2
million cells per replicate and condition were FACS sorted (Venus+, dsRed+),
and genomic DNA was extracted from all samples using the Gentra Puregene
Cell Kit (QIAGEN). Deep-sequencing template libraries were generated for
each replicate by PCR amplification of shRNA guide strands. To allow for multi-
plexed illumina sequencing, forward primers located in the loop region of
the miR30 cassette were barcoded 30 of the p7 adaptor sequence (forward
primer: 50-CAAGCAGAAGACGGCATACGA - 8 nt barcode - TAGTGAAGCCA
CAGATGTA-30). The p5-adaptor-coupled reverse primer was placed 30 of the
miR30 shRNA cassette within the TRMPV-Neo backbone to achieve exclusive
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Effective MEK Inhibition in KRAS Mutant Tumorsamplification of shRNAs that were part of the library and avoid amplification of
the miR30-based p53 shRNA present in the screen cell line (reverse primer:
50-AATGATACGGCGACCACCGACGGTAGAATTGCTAGAATTG-30). All PCR
reactions per barcode were pooled and subjected to Agencourt AMPure XP
bead purification (Beckman Coulter). Libraries were analyzed on an Illumina
2000 Genome Analyzer (Illumina) using the custom primer miR30EcoRISeq 50-
TAGCCCCTTGAATTCCAGGCAGTAGGCA-30. Sequence processingwas per-
formed using a custom script developed by the MSKCC Bioinformatics Core,
and downstream analysis was performed in R (http://cran.r-project.org/), and
the fold change of shRNA representation was calculated by comparing normal-
ized shRNA reads at Tf to normalized reads at T0. To identify synthetically lethal
interactions, fold change in the presence of theMEK inhibitor was set in relation
to the fold change in the absence of the MEK inhibitor.
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